# US 2013/0158073 A1 · Methods Of Diminishing Co-Abuse Potential

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0158073 A1
- Document ID: US20130158073A1
- Status: Published application
- Kind: A1
- Application number: 13/765,994
- Filed: 2013-02-13
- Published: 2013-06-20
- Earliest claimed: 2004-04-26
- Inventors: Vikram Khetani; Herbert Faleck
- Web page: https://patentgrep.com/patent/US20130158073A1

## CPC

- A61K 31/4458: only substituted in position 2, e.g. methylphenidate
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/30: for treating abuse or dependence
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Methods of diminishing or eliminating the co-abuse of a methylphenidate drug comprising identifying a patient or patient group suspected or likely to abuse said methylphenidate drug in combination with a substance known or suspected to give rise to l-ethylphenidate or psychotropic effect when ingested in the combination and making available to said patent or patient group said methylphenidate drug substantially free of l-threo methylphenidate.

## Claims

### Claim 1

A method of reducing co-abuse of a methylphenidate drug and ethyl alcohol comprising:
identifying a patient or patient group abusing the methylphenidate drug and ethyl alcohol; and
providing to the patient or patient group a methylphenidate drug substantially free of 1-threo methylphenidate.

### Claim 2 (depends on 1)

The method of claim 1 wherein said methylphenidate drug is made available orally, intravenously, parenterally, via an aerosol or gaseous suspension, or transdermally.

### Claim 3 (depends on 2)

The method of claim 2 comprising up to 10 mg of methylphenidate drug.

### Claim 4 (depends on 2)

The method of claim 2 comprising up to 5 mg of methylphenidate drug.

### Claim 5 (depends on 2)

The method of claim 2 comprising up to 3 mg of methylphenidate drug.

### Claim 6 (depends on 2)

The method of claim 2 comprising from about 0.1 mg to about 100 mg of methylphenidate drug.

### Claim 7 (depends on 1)

The method of claim 1 wherein said patient has or is suspected of having ADD or ADHD.